Dediabetes Logo
Evidence Hub
Learn what works
Evidence Explorer
Search the complete evidence graph
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Semaglutide reduces insulin doses in type 1 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated August 22, 2026

Key finding

There was a significant 22.6% reduction in TDD (95% CI -28.3 to -17.0).

This study evaluated the effects of semaglutide on insulin doses and weight loss in adults with type 1 diabetes and obesity, finding significant reductions in insulin doses.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

High Risk

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of semaglutide on insulin doses and weight loss in adults with type 1 diabetes and obesity, finding significant reductions in insulin doses.

Clinical relevance

This study highlights the potential of semaglutide as a treatment option for adults with type 1 diabetes and obesity, suggesting it may help manage insulin requirements and dietary intake. These findings could lead to improved diabetes management strategies and better health outcomes for this population.

Keep in mind

Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Lack of significant changes in the placebo group limits comparative analysis.

Published in

Journal Reference

Publication details and source links for this paper.

Kagan EK, Halis KA, Davida K, et al. Semaglutide Treatment in Adults with Type 1 Diabetes and Obesity: Insulin Dose Reduction and Weight Loss. Diabetes Care. 2026;49(5):718-723. doi:10.2337/dc25-2249

View DOIView on PubMedView on PMC

Main Effects

Total daily insulin dose (TDD) reduced by 22.6% (p=0.001).

Bolus insulin dose decreased by 30.5%.

Basal insulin dose decreased by 15.6%.

Daily carbohydrate intake decreased by 30 g.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Basal insulin dose, Bolus insulin dose, Carbohydrate intake, and 1 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Basal insulin dose

Evidence topic

Adverse Events and Safety

Primary intervention

Semaglutide

Primary outcomes

  • Basal insulin dose
  • Bolus insulin dose
  • Carbohydrate intake

Evidence topics

Adverse Events and SafetyGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

Basal insulin doseBolus insulin doseCarbohydrate intake

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 65

2

Related topics

4

Evidence pairs

232

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 4 evidence relationships
  • Includes primary outcome data
  • Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and Insulin Resistance

Related evidence

Evidence topic

Adverse Events and Safety

Save evidence

Evidence topic

GLP-1 Receptor Agonists

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Basal insulin dose

Semaglutide → Basal insulin dose

Semaglutide → Basal insulin dose

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
93
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Bolus insulin dose

Semaglutide → Bolus insulin dose

Semaglutide → Bolus insulin dose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
85
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Total daily insulin dose

Semaglutide → Total daily insulin dose

Semaglutide → Total daily insulin dose

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Carbohydrate intake

Semaglutide → Carbohydrate intake

Semaglutide → Carbohydrate intake

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Semaglutide reduced total daily insulin dose by 22.6%.
  • Bolus insulin dose decreased by 30.5%.
  • Carbohydrate intake reduced from 137 g to 107 g.
who this applies

Who this applies to

  • Adults aged 18 and older with type 1 diabetes.
  • Individuals with obesity as defined by clinical criteria.
keep in mind

Keep in Mind

  • Results may not apply to younger populations or those without obesity.
  • Further studies are needed to confirm long-term effects.
  • The study's findings are based on a specific population and may not generalize to all individuals with type 1 diabetes.
between the lines

Between the Lines

  • Limited sample size may affect generalizability.
  • Short duration of the study may not capture long-term effects.
  • Lack of significant changes in the placebo group limits comparative analysis.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and Basal insulin dose, GLP-1 Receptor Agonists and Insulin Resistance.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve insulin resistance?

Strong Evidence

GLP-1 Receptor Agonists appears to improve Insulin Resistance.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Total daily insulin dose

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
7 supporting studiesUpdated: Aug 2026
View Full Evidence

Does Semaglutide improve basal insulin dose?

Moderate Evidence

Semaglutide appears to improve Basal insulin dose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Basal insulin dose

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence

Does Semaglutide improve bolus insulin dose?

Emerging Evidence

Semaglutide appears to improve Bolus insulin dose.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Bolus insulin dose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence

Does Semaglutide improve carbohydrate intake?

Emerging Evidence

Semaglutide appears to improve Carbohydrate intake.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Carbohydrate intake

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Adverse Events and Safety Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and Basal insulin doseAll studies on Semaglutide and Total daily insulin doseAll studies on Semaglutide and Bolus insulin doseAll studies on Semaglutide and Carbohydrate intake

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.